Manulife (Manufacturers Life Insurance)
KLRS

Manulife (Manufacturers Life Insurance)’s Kalaris Therapeutics KLRS Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-928
Closed -$16.1K – 3054
2024
Q1 		$16.1K Sell
928
-72
-7% -$1.18K ﹤0.01% 2931
2023
Q4 		$15.6K Buy
+1,000
New +$39.4K ﹤0.01% 2949
2023
Q2 		– Sell
-596
Closed -$54K – 3073
2023
Q1 		$54K Hold
596
– – ﹤0.01% 2851
2022
Q4 		$70.3K Buy
+596
New +$101K ﹤0.01% 2871
2022
Q2 		– Sell
-585
Closed -$90.7K – 3164
2022
Q1 		$90.7K Sell
585
-116
-17% -$23.1K ﹤0.01% 2970
2021
Q4 		$208 Buy
701
+8
+1% +$3.71K ﹤0.01% 2868
2021
Q3 		$400K Sell
693
-48
-6% -$22.2K ﹤0.01% 2450
2021
Q2 		$336K Buy
741
+3
+0.4% +$1.55K ﹤0.01% 2730
2021
Q1 		$397K Buy
738
+260
+54% +$219K ﹤0.01% 2438
2020
Q4 		$423K Buy
478
+58
+14% +$44.6K ﹤0.01% 2300
2020
Q3 		$266K Buy
+420
New +$287K ﹤0.01% 2382

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s KLRS Position: Q2 2024 in Review

Manulife (Manufacturers Life Insurance) sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 928 shares — an estimated $16.1K sold.

Manulife (Manufacturers Life Insurance) first reported a position in KLRS in Q3 2020 and held it in 11 quarters. The position peaked at $423K in Q4 2020. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Manulife (Manufacturers Life Insurance) reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 928 Kalaris Therapeutics shares in Q2 2024, an estimated $16.1K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 11 quarters.
  • Manulife (Manufacturers Life Insurance)'s Kalaris Therapeutics position peaked at $423K in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2024, filed 14 Aug 2024.